CRISPR ...

近日，Beamion LUNG-1的1b期剂量扩展试验结果发表于《新英格兰医学杂志》（NEJM），表明在既往接受过治疗的HER2突变晚期或转移性NSCLC患者中，使用宗格替尼可获得良好的临床获益，在最终选定的120 ...

The medicine, Trastuzumab deruxtecan, was already available for some breast and stomach cancers. It has been approved to ...

阿斯利康（AstraZeneca PLC）于周三宣布，其最新试验评估的Enhertu在高风险、局部晚期HER2阳性早期乳腺癌患者中获得了积极的高水平结果。该公司表示，Destiny-Breast11三期试验显示，Enhertu（trastuzumab deruxtecan）联合使用紫杉醇、曲妥珠单抗和帕妥珠单抗，较现行标准治疗在病理完全缓解率上实现了统计学和临床上显著的改善。 Enhertu由阿斯 ...

Topline results from the Phase III DESTINY-Breast11 trial show that Enhertu (trastuzumab deruxtecan) followed by paclitaxel, ...

Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...

--(BUSINESS WIRE)-- Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab ...

Puma Biotechnology announced Phase I data of trastuzumab deruxtecan plus neratinib in solid tumors with HER2 alterations was ...

AstraZeneca has announced encouraging high-level results from its DESTINY-Breast11 phase 3 clinical trial, which evaluated ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...